Quarterly Financial Results for Q2 2026: This 10-Q filing contains Gilead Sciences' unaudited financial statements and results for the six-month period ended June 30, 2026, including consolidated balance sheets, statements of income, and statements of equity. Product and Royalty Revenue Segments: The filing includes detailed breakdowns of revenue by product category and royalty/contract revenues…

Our analysis rates this filing NEUTRAL. Gilead Sciences presents a MODERATE concern profile reflecting a stable but operationally challenged position. The primary concern is the material deterioration in receivables aging (38-day increase), which suggests either extended payment terms to maintain…

Concern level: ELEVATED (4.8/10). Key factors: Trade receivables collection period deteriorated 17.4% (218 to 256 days) - indicates potential customer financial stress or pricing pressure in core markets; Concentrated product portfolio with multiple HIV product lines (Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Yeztugo) suggesting therapeutic area concentration risk; Extended receivables aging…

Notable risk changes: Receivables aging deteriorated from 218 to 256 days - 17.4% increase in collection period suggests potential customer financial stress or pricing pressure in core markets; Filing structure indicates multiple HIV product lines (Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Yeztugo) with geographic segmentation - suggests revenue concentration risk across limited product portfolio; Document is Q2…

The model predicts GILD will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.